Health Care [ 7/12 ] | Biotechnology [ 49/74 ]
NASDAQ | Common Stock
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients.
The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products.
It has collaboration agreements primarily with Janssen PharmaceuticaN. V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International.
Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 5, 26 | 0.38 Increased by +31.03% | -0.04 Increased by +1.05 K% |
| Feb 25, 26 | 0.29 Decreased by -72.38% | 0.41 Decreased by -29.27% |
| Oct 28, 25 | 0.49 Decreased by -32.88% | 0.30 Increased by +63.33% |
| Jul 29, 25 | 0.68 Decreased by -2.86% | 0.40 Increased by +70.00% |
| May 1, 25 | 0.29 Decreased by -32.56% | 0.24 Increased by +20.83% |
| Feb 12, 25 | 1.05 Increased by +377.27% | 0.76 Increased by +38.16% |
| Oct 24, 24 | 0.73 Increased by +14.06% | 0.71 Increased by +2.82% |
| Jul 24, 24 | 0.70 Increased by +27.27% | 0.71 Decreased by -1.41% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 392.91 M Increased by +28.19% | -66.48 M Decreased by -395.94% | Decreased by -16.92% Decreased by -330.86% |
| Dec 31, 25 | 384.55 M Decreased by -10.57% | 49.34 M Decreased by -66.32% | Increased by +12.83% Decreased by -62.34% |
| Sep 30, 25 | 394.19 M Increased by +4.24% | 82.76 M Decreased by -10.41% | Increased by +21.00% Decreased by -14.06% |
| Jun 30, 25 | 390.66 M Decreased by -2.12% | 87.10 M Decreased by -4.66% | Increased by +22.30% Decreased by -2.59% |
| Mar 31, 25 | 306.51 M Decreased by -12.52% | 22.46 M Decreased by -39.00% | Increased by +7.33% Decreased by -30.27% |
| Dec 31, 24 | 429.99 M Increased by +13.91% | 146.50 M Increased by +29.90% | Increased by +34.07% Increased by +14.04% |
| Sep 30, 24 | 378.14 M Decreased by -0.73% | 92.38 M Increased by +93.44% | Increased by +24.43% Increased by +94.87% |
| Jun 30, 24 | 399.13 M Decreased by -35.35% | 91.36 M Decreased by -61.46% | Increased by +22.89% Decreased by -40.39% |